Clinical trial · Observational
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
NCT01355003CI-TRIAL-00018830terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Merck Sharp \& Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing surveillance (PMS) study
Summary
Brief summary (as posted)
This study will collect safety information on the use of GARDASIL™ in the Philippines.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillomavirus Infections | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- All Participants
- description
- Participants who were vaccinated with GARDASIL™ by their physician
Primary outcomes (1)
- measure
- Number of participants with adverse events following any dose of vaccine
- timeFrame
- At least 30 days following any vaccine dose
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 9 Years
- Maximum age
- 46 Years
Show eligibility criteria text
Inclusion Criteria: * Received GARDASIL™
References
Publications (0)
Data not yet available
No reference posted for this study.